



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Synthesis of coumarin derivatives and their cytoprotective effects on *t*-BHP-induced oxidative damage in HepG2 cells



Tomomi Ando^a, Mina Nagumo^b, Masayuki Ninomiya^{a,b}, Kaori Tanaka^{c,d}, Robert J. Linhardt^e, Mamoru Koketsu^{a,b,*}

^a Department of Materials Science and Technology, Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan

^b Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan

^c Division of Anaerobe Research, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan

^d United Graduate School of Drug Discovery and Medicinal Information Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan

^e Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, United States

ARTICLE INFO

Keywords:

Coumarin

Cytoprotection

Human hepatoma HepG2 cell

ABSTRACT

Coumarins are ubiquitous in higher plants and exhibit various biological actions. The aim of this study was to investigate the structure-activity relationships of coumarin derivatives on *tert*-butyl hydroperoxide (*t*-BHP)-induced oxidative damage in human hepatoma HepG2 cells. A series of coumarin derivatives were prepared and assessed for their cytoprotective effects. Among these, a caffeoyl acid-conjugated dihydropyranocoumarin derivative, caffeoyllomatin, efficiently protected against cell damage elicited by *t*-BHP. Our findings suggest that caffeoyllomatin appears to be a potent cytoprotective agent.

Coumarins constitute a class of polyphenols that occur naturally in higher plants. Their framework is comprised of fused benzene and α -pyrone rings, which are produced from the shikimic acid pathway.¹ Coumarins assume prominent functions in plant physiology, chemical defense, and interactions between plants and their environment. During winter, some coumarins inhibit seed germination by suppressing mitosis until growth conditions are favorable.² In addition, coumarins act as phytoalexins against invading microbial pathogens and as defensive compounds against insect herbivores.^{3–6} Thus, coumarin constituents are of primary importance in plants.

In the view of the therapeutic use of coumarins in human health, coumarins have been tested as anticoagulant, anti-inflammatory, cardiovascular, and neuroprotective agents.^{7,8} Dicoumarol, a fermentation product in *Medicago sativa* is a lead compound of warfarin, which is the most frequently used oral anticoagulant worldwide.⁹ A linear-type furanocoumarin, methoxsalen (also called ammoidin and xanthotoxin), in *Ammi majus* is a drug used to treat psoriasis, eczema, and vitiligo in clinical practice.¹⁰ It has been reported that simple plant coumarins, esculetin and scoparone play a critical part in the prevention of oxidative stress.^{11,12}

Linear-type and angular-type *p*-coumaric acid-conjugated dihydrofuranocoumarin and dihydropyranocoumarin derivatives (angelmarin, coumaroyllomatin, and secorin) have been isolated from *Angelica pubescens*,¹³ *Lomatium columbianum*,¹⁴ and *Seseli coronatum*,

respectively.¹⁵ While diversely modified coumarins have been identified from plants, only a few phenylpropanoid-conjugated coumarin derivatives have been isolated.¹ This study focuses on exploring structure-activity relationships of these rare coumarin derivatives with respect to their protective effects on *tert*-butyl hydroperoxide (*t*-BHP)-induced hepatic damage.


An isoprenyl unit and an *ortho*-substituted hydroxy group participate in the formation of either five-membered dihydrofuran or six-membered dihydropyran rings, commonly encountered in natural products. The cyclization has been postulated to involve an epoxide intermediate, so that nucleophilic attack of the neighboring hydroxy group on to the epoxide group can lead to formation of those heterocycles. We therefore embarked on the preparation of osthenol and demethylsuberosin as synthetic precursors from readily available umbelliferone. The synthetic route is shown in Scheme 1. Because direct and selective isoprenylation at the C6 or C8 positions of umbelliferone is difficult to achieve, we employed an approach using a Claisen rearrangement.¹⁶ The *O*-1,1-dimethyl-2-propynylation of umbelliferone using 3-chloro-3-methyl-1-butyne, DBU, and a catalytic amount of CuCl₂·2H₂O furnished compound **1** (60% yield), which upon Lindlar reduction afforded 1,1-dimethyl-2-propenyl product **2** in 76% yield. The Claisen rearrangement of **2** in water at 75 °C offered ready access to the desired osthenol **3** and demethylsuberosin **4** in 65% and 12% yields, respectively.

* Corresponding author at: Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
E-mail address: koketsu@gifu-u.ac.jp (M. Koketsu).


<https://doi.org/10.1016/j.bmcl.2018.06.018>

Received 26 March 2018; Received in revised form 2 June 2018; Accepted 11 June 2018
Available online 12 June 2018

0960-894X/ © 2018 Elsevier Ltd. All rights reserved.



Scheme 1. Synthesis of osthenol and demethylsuberosin.

Scheme 3. Synthesis of *p*-coumaroyl derivatives.

Scheme 2. Synthesis of various dihydrofurano- and dihydropyrano-coumarins.

The cyclization started with the *m*CPBA-mediated epoxidation of the isoprenyl group in **3** and **4** to form the epoxide intermediates, which were immediately converted under basic conditions into dihydrofurano products, columbianetin **5** in 81% yield and marmesin **7** in 41% yield (Scheme 2).¹⁷ In contrast, epoxide opening under acidic conditions happened at the more substituted end, to generate the dihydropyrano products, lomatin **6** in 79% yield and decursinol **8** in 71% yield.

After the successful formation of dihydrofurano-fused and dihydropyrano-fused coumarins, the stage was set for the synthesis of *p*-coumaric acid-conjugated derivatives (Scheme 3). Esterification of compounds **5–8** with *O*-TBS-protected *p*-coumaric acid chloride in the presence of K_2CO_3 and subsequent deprotection by means of TBAF afforded the *p*-coumaroyl derivatives, angelmarin (**9**, 49% yield), coumaroyllomatin (**10**, 49% yield), secorin (**11**, 64% yield), and coumaroyldecursinol (**12**, 49% yield). In addition, from lomatin (**6**), a series of phenylpropanoid-conjugated derivatives **13–18** were similarly prepared in 38–90% yields by various esterification reactions with acid chlorides and deprotection (if needed). Their chemical structures are presented in Fig. 1.

Because all compounds (**5–18**) were non-toxic to HepG2 cells at a concentration of 10 μ M (data not shown), we examined their possible




Fig. 1. Chemical structures of phenylpropanoid-conjugated coumarins.

protective effects against *t*-BHP-induced cytotoxicity on human hepatoma HepG2 cells, by preincubating the cells in the presence or absence of these compounds.^{18–20} The viability of HepG2 cells was measured by CCK-8 assay.²¹ A large decrease in cell viability (22%) was observed upon treatment of HepG2 cells with 100 μ M *t*-BHP (Fig. 2A). Pretreatment with compound **16** (10 μ M) displayed a powerful protection (cell viability: 86%) against cell death resulting from *t*-BHP exposure. The compound **16** was more effective than quercetin (cell viability: 62%), which served as a positive control. In contrast, other synthetic derivatives tested were ineffective in this concentration. Methyl caffeate (**19**), a substructure of **16** showed a weak effect (cell viability: 31%). Even with 1 mM *t*-BHP exposure to the cells, **16** exhibited an excellent protective effect (cell viability: 39%, Fig. 2B). For assessment of mitochondrial membrane potential changes, we stained the cells with Rhodamine 123 (Rh123).²² The Rh123-staining images observed under fluorescence microscopy are shown in Fig. 3. Mitochondrial membrane potential decreased after treatment with *t*-BHP (100 μ M) compared to the untreated control, which may be due to the depolarization of the




Fig. 2. Cytoprotective effects of coumarin derivatives (10 μM) on *t*-BHP-induced cytotoxicity in HepG2 cells. Cells were pre-treated with samples for 1 h, and were subsequently exposed to *t*-BHP for 3 h. Values (mean ± S.D., $n = 3$) are expressed as a percentage relative to viability of cells treated with *t*-BHP alone. * $p < 0.05$ and ** $p < 0.01$, respectively (vs. cells treated with *t*-BHP alone). A: 100 μM *t*-BHP exposure; B: 1 mM *t*-BHP exposure.

membrane. The fluorescence intensity of compound (16)-pretreated cells was no different from that of untreated control, indicating the mitochondrial protective nature of the compound.

A catechol group is known to possess antioxidant activity and is a common substructure in caffeoyllomatin (16), methyl caffeate (19), and quercetin (Q). DPPH radical scavenging activity of the three compounds was evaluated to confirm whether the catechol group makes a major contribution to the cytoprotective effects of the compounds.²³ These compounds exerted the antioxidant capacity and their EC_{50} values were 3.06 μM for 16, 1.50 μM for 19, and 0.17 μM for quercetin. Detoxification of harmful oxygen species by the catechol group of 16

contributed to the cytoprotective effect.

Nuclear factor erythroid 2-related factor 2 (Nrf2) has emerged as a transcription factor that maintains cellular homeostasis. The Keap1-Nrf2 signaling pathway evokes an adaptive response to oxidative stress that serves to enhance cell survival.^{24–26} Previous studies have shown that several plant phenolics regulate the Keap1/Nrf2 complex.^{27,28} Our computational molecular simulations demonstrated that 16 favorably docked to the Kelch domain of Keap1 protein (PDB ID: 4L7B)²⁹ with free binding energy of -7.08 kcal/mol (see [Supplementary data](#)).

In conclusion, we have presented the practical synthesis of naturally occurring coumarin derivatives and assessment of their cytoprotective




Fig. 3. Mitochondrial membrane potential changes observed with Rhodamine 123 staining. A: untreated control; B: 100 μM *t*-BHP exposure; C: pretreatment with caffeoyllomatin 16 before 100 μM *t*-BHP exposure; D: pretreatment with quercetin (Q) before 100 μM *t*-BHP exposure.

effects. Notably, caffeoyllomatins (**16**) attenuated *t*-BHP-induced HepG2 cell injury. The discovery of **16** as a hepatoprotective agent may lead to further development of natural product-derived chemotherapeutic drugs for treatment of liver disorders.

Acknowledgment

We gratefully thank Assistant Prof. You Fukka (Division of Antioxidant Research, Life Science Research Center, Gifu University) for providing HepG2 cells.

A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2018.06.018>.

References

1. Bourgaud F, Hehn A, Larbat R, et al. *Phytochem Rev*. 2006;5:293.
2. Zobel AM, Brown SA. *Allelopathy J*. 1995;2:9.
3. Camm EL, Wat C-K, Towers GHN. *Can J Bot*. 1976;54:2562.
4. Matern U. *Planta Med*. 1991;57:S15.
5. Gutiérrez-Mellado M-C, Edwards R, Tena M, Cabello F, Serghini K, Jorrín J. *J Plant Physiol*. 1996;149:261.
6. Zeng RS, Wen Z, Niu G, Schuler MA, Berenbaum MR. *J Chem Ecol*. 2007;33:449.
7. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. *Curr Med Chem*. 2005;12:887.
8. Sandhu S, Bansal Y, Silakari O, Bansal G. *Bioorg Med Chem Lett*. 2014;22:3806.
9. Gomez-Outes A, Suarez-Gea ML, Calvo-Rojas G, et al. *Curr Drug Discov Technol*. 2012;9:83.
10. Parrish JA, LeVine MJ, Fitzpatrick TB. *Int J Dermatol*. 1980;19:379.
11. Lin W-L, Wang C-J, Tsai Y-Y, Liu C-L, Hwang J-M, Tseng T-H. *Arch Toxicol*. 2000;74:467.
12. Atmaca M, Bilgin HM, Obay BD, Diken H, Kelle M, Kale E. *J Physiol Biochem*. 2011;67:569.
13. Awale S, Nakashima EMN, Kalauni SK, et al. *Bioorg Med Chem Lett*. 2006;16:581.
14. Nielsen BE, Jensen E. *Phytochemistry*. 1976;15:1049.
15. Dukhovlina LI, Sklyar YE, Pimenov MG. *Khim Prir Soedin*. 1974:782.
16. Beare Kaitlin D, McErlean Christopher SP. *Tetrahedron Lett*. 2013;54:1056.
17. Inagaki R, Ninomiya M, Tanaka K, Koketsu M. *ChemMedChem*. 2015;10:1413.
18. Kinjo J, Hitoshi M, Tsuchihashi R, et al. *J Nat Med*. 2006;60:36.
19. Jung J-W, Ko W-M, Park J-H, et al. *Arch Pharm Res*. 2015;38:2066.
20. Pardede A, Adfa M, Kusnanda AJ, Ninomiya M, Koketsu M. *Med Chem Res*. 2017;26:2074.
21. Kakumu A, Ninomiya M, Efdi M, et al. *Bioorg Med Chem Lett*. 2014;24:4286.
22. Scaduto Jr RC, Grotyohann LW. *Biophys J*. 1999;76:469.
23. Kato K, Ninomiya M, Tanaka K, Koketsu M. *J Nat Prod*. 2016;79:1808.
24. Zhang DD. *Drug Metab Rev*. 2006;38:769.
25. Klaassen CD, Reisman SA. *Toxicol Appl Pharmacol*. 2010;244:57.
26. Taguchi K, Motohashi H, Yamamoto M. *Genes Cells*. 2011;16:123.
27. Magesh S, Chen Y, Hu L. *Med Res Rev*. 2012;32:687.
28. Liu MM, Huang KM, Qian L, et al. *Phytomedicine*. 2018;40:1.
29. Jnoff E, Albrecht C, Barker JJ, et al. *ChemMedChem*. 2014;9:699.